ABSTRACT We transformed BALB/3T3 mouse cells with cellular DNA extracted from the Meth A sarcoma, a 3-methylcholanthrene-induced tumor ofBALB/c mice, and asked whether foci arising in the transfection possess the previously defined Meth A tumor-specific transplantation antigen (TSTA). Five of eight foci selected from one experiment possessed Meth A TSTA. DNA extracted from one of the five TSTA-positive clones was used in secondary rounds oftransfection transformation. Four out of five foci tested from the secondary transfections possessed Meth A TSTA. These results suggest that in the Meth A sarcoma a transforming gene and a genetic determinant of TSTA are intimately related: they may be identical or very closely linked; alternatively, a particular transforming gene might induce the expression of a particular TSTA. Another possible explanation for these results is that the cotransfer of certain cellular genes by DNA transfection is considerably higher than predicted from the limited studies presently available.
To investigate the relationship between the genetic determinants of TSTAs and the transformed phenotype, we transformed BALB/3T3 mouse cells with DNA from the 3-methylcholanthrene-induced Meth A sarcoma (5), using the calcium phosphate precipitation technique (7) (8) (9) (10) , and asked whether the transformants possess the previously defined Meth A TSTA (5, 6, 11, 12) . Because the stable expression of mammalian cell genes after DNA transfection is very inefficient, one would expect the frequency of cotransfer of the two phenotypes, transformation and TSTA, to be only 0. 01-0. 001 ifthey are specified by unlinked genes (13, 14) . However, if the two phenotypes have common or linked determinants, one would expect a high frequency of cotransfer.
The Meth A sarcoma was selected for these experiments because its TSTA has been well characterized immunologically and biochemically and shown to be distinct from TSTAs of all other syngeneic neoplasms assayed to date (5, 6, 11, 12) . The tumor was induced in a BALB/c mouse in 1960 (5) . Within a year ofits isolation an ascites form ofthe tumor was established, and both the solid and ascites forms possess the Meth A TSTA. Cell lines have been established from both forms of the tumor, and these lines possess Meth A TSTA. The ascites form of Meth A and its derivative cell line appear to be negative for expression of type C viruses or. viral antigens (15) .
Here we report that the two phenotypes transformation and Meth A TSTA show a high frequency of cotransfer through two successive rounds of DNA transfection.
MATERIALS AND METHODS DNA Transfection. Cellular DNA was extracted (16) from the following tissue culture cell lines: mouse NIH/3T3 (17) ; BALB/3T3 clone 7 (ref. 18 ; see below); mouse 64F3 clone 7, a nonproducer mink cell transformed by the replication-defective Gardner-Arnstein feline sarcoma virus (FeSV) (19) ; and a tissue culture line derived from the ascites form of the Meth A sarcoma Meth A (a) (15) .
Recipient cells were a subclone of BALB/3T3 clone A31 (18) designated BALB/3T3 clone 7 and were grown in Dulbecco's modified Eagle's medium with 10% calf serum.
DNA was precipitated with calcium phosphate essentially as described (7, 20) . Specifically, recipient cells were seeded at 1-1.5 X 106 per 10-cm dish for some experiments or 4 X 105 per 6-cm dish for others, and 40 Ag of high molecular weight DNA was sheared by two passages through a 20 gauge hypodermic needle and resuspended in 1.25 ml ofprecipitation buffer, or 20 yg of DNA in 0.625 ml of buffer was added to 6.25 ml or 3.5 ml of medium in 10-cm or 6-cm dishes, respectively. In each experiment, 60-160 ,ug of each DNA was used. Five hours after addition of the DNA, the plates were washed and the cells were glycerol shocked to enhance transfection efficiency (21): 17% (vol/vol) glycerol containing, per liter, 8 g of NaCl, 5 g of Hepes, 0.37 g of KCl, and 1 g of dextrose (pH 7.0) was applied for 1 min and 40-45 sec, the shock was quenched by addition of medium, the plates were washed, and the medium was replaced. Six to 10 hr later, the cells were treated with trypsin and reseeded at 2-3 x 105 per 10-cm dish or 105per 6-cm dish. Foci were observed at 14 days on live cells, 17 days-6 weeks on fixed cells. Cells were fixed with Formalin/phosphate-buffered saline and stained with cresyl violet acetate (1% aqueous). Transformed foci were usually picked at 3-4 weeks by using glass cloning cylinders with an inner diameter of 5.5
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Tissue culture-propagated transfectants and control cell lines were used to immunize BALB/c females 8-12 weeks of age. Usually 2-3 x 106 x-irradiated cells [10, Table 3 ). Inhibition of Meth A sarcoma growth with BMA-11-7-a was significant at P < 0.02. The immunogenicities of two other subclones, BMA-11-5a and BMA-11-9a, were also assayed against Meth A challenge; BMA-11-5a was immunogenically comparable to BMA-11-7a, whereas BMA-11-9a did not immunize.
however, sister plates that were not transfected at all also possessed foci, and thus we assume that these foci arose spontaneously. Table 2 and graphically in Fig. 3 , and the results for all the transfectants tested are summarized in Table 4 . That the protection against tumor induction Table  3 , immunization of BALB/c mice with Meth A sarcoma cells inhibited tumor growth by the transformant designated BMA-11-7a. Furthermore, the mutual cross-protection conferred between the Meth A sarcoma and the transfectant BMA-11-7a was stable after 15 passages in vivo ofthe BMA-11-7a line ( Table 3) . Four of five secondary transformants. induced in BALB/3T3
with DNA from the Meth A transformant designated BMA-11-7a were found to possess the Meth A TSTA (Table 4) .
DISCUSSION
Limited studies to determine the frequency of cotransfer of mammalian cell genes by DNA transfection have indicated-that BMA-5 BMA-6 BMA-6-9-a BMA-9 BMA-9-la BMA-11 BMA-11-5a BMA-11-7a BMA-11-9a BMA-12
Secondary transfectants § Table 1 ). In Exp. 1, cells from two plates transfected with a total of 80 ,g of Meth A DNA were pooled and reseeded at 2 x 105 on 25 10-cm dishes. Twelve foci appeared on 10 of the 25
plates. tMice were immunized subcutaneously with. x-irradiated (10,000 roentgens) cells (2-3 x 10' cells) three times and challenged with 104
Meth A sarcoma cells 7 days after the last immunization. Transfectants designated + gave at least 80% inhibition of Meth A tumor growth. * Foci inducedby Meth A DNA were picked and the resulting cell lines were designated BMA-. Subclones of these lines are given the name *of the parent line followed by the subclone number and an 'a" to indicate that the subclone was selected in agar. § Foci induced by BMA-11-7a DNA were cloned and the resulting cell lines were designated SBMA-. In transfection Exp. 5, six 6-cm dishes were transfected with 20 ug each of DNA from the primary transfectant BMA-11-7a. Each transfected plate was trypsinized separately and the cells were reseeded at 105 per 6-cm dish to yield a total of 38 dishes. Eight foci appeared on these plates. The four SBMA foci from Exp. 5 that were analyzed for Meth A TSTA were obtained from different transfected plates and therefore must have arisen independently. ¶BALB/3T3 control: BALB/3T3 cells were transfected with NIH/ 3T3 DNA but no foci were observed. B-3, B-10, and B-11: foci arising on plates transfected with BALB/3T3 DNA. These are believed to be spontaneously arising foci (see text).' MF-: MF-1, MF-3, and MF-12 all derived from foci induced by DNA from FeSV-transformed nonproducer mink cell. MF-1-3a is a subclone of MF-1 and was selected in agar.
when one phenotype is selected, a second unselected marker will be present in the transfectants at a frequency of approximately 0.01-0.001 (13, 14) . Thus the studies reported here, in which we selected for the transformed suggests the feasibility of this approach.
In vivo, recognition of TSTAs is mediated by the cellular immune system, and in general it has proved difficult to elicit a serological response to a TSTA or to demonstrate that anti-tumor sera recognize the same determinants that elicit tumor rejection (5, 24). However, DeLeo et aL (15) succeeded in raising an antiserum that is specifically cytotoxic for the Meth A sarcoma, and recent evidence suggests that the serologically defined Meth A antigen (TSSA) and Meth A TSTA may be the same or closely related (25) . So far it has not been possible to immunoprecipitate the Meth A TSSA. It should be noted that this antigen is thus distinct, by serological definition, from the p53 protein that is precipitated from many transformed cells by the serum that also specifically recognizes Meth A TSSA in a cytotoxic test (26) . The Meth A transfectants described in this report have been assayed for the presence ofthe Meth A TSSA, and it appears that some possess the serologically defined Meth A antigen, although the number ofpositive clones is lower than the number positive for Meth A TSTA (unpublished results).
The simple interpretation of our findings, namely that genes specifying TSTAs may in some cases be intimately associated with or identical to transforming genes, seems surprising in light of recent findings suggesting that the number of genes responsible for oncogenic transformation may be quite small, whereas TSTAs are distinct for each tumor. Clearly it will be of great interest to determine whether the transformed phenotype and TSTAs cotransfer when DNA from carcinogen-induced murine tumors 
